Table 3.

∆∆QTcI Across Treatments and Time points Postdosing (mean ± 90% CI)^a

			90% CI				90% CI
	Mean	SE	Lower	Upper	Mean	SE	Lower	Upper
Time	75 mg lomitapide adjusted for placebo				200 mg lomitapide adjusted for placebo
1	−1.2	0.8	−2.5	0.2	1.8	1.5	−0.7	4.2
2	−1.2	0.8	−2.5	0.1	0.3	1.4	−2.0	2.6
3	−2.1	0.9	−3.6	−0.5	1.9	1.5	−0.5	4.3
4	−1.8	1.0	−3.5	−0.1	−0.1	1.3	−2.2	2.1
5	−1.8	1.0	−3.4	−0.2	−0.1	1.3	−2.2	2.1
7	−2.6	1.2	−4.6	−0.5	1.3	1.2	−0.8	3.3
12	−1.0	0.9	−2.5	0.5	2.8	1.2	0.9	4.7
24	1.4	0.9	−0.2	3.0	1.0	1.3	−1.1	3.1
	75 mg lomitapide + ketoconazole
Time	adjusted for ketoconazole				Ketoconazole adjusted for placebo
1	0.4	1.5	−2.1	2.9	4.7	1.5	2.2	7.2
2	−1.7	1.4	−4.0	0.6	5.9	1.4	3.6	8.2
3	−1.2	1.5	−3.6	1.2	6.5	1.5	4.1	8.9
4	−0.8	1.3	−2.9	1.4	4.1	1.3	2.0	6.2
5	−0.4	1.3	−2.5	1.6	4.2	1.2	2.2	6.3
7	−0.8	1.2	−2.9	1.2	2.7	1.2	0.7	4.7
12	0.6	1.2	−1.4	2.5	2.4	1.2	0.5	4.3
24	2.3	1.2	0.3	4.4	1.1	1.2	−0.9	3.1
Time	Moxifloxacin adjusted for placebo
0.25b	−0.3	1.4	−2.7	2.1
0.5b	6.8	2.0	3.5	10.2
0.75b	10.4	1.5	7.9	12.9
1	12.4	1.5	9.9	14.9
2	10.7	1.4	8.4	13.0
3	11.6	1.5	9.2	14.0
4	10.3	1.3	8.2	12.4
5	8.2	1.3	6.2	10.3
7	10.0	1.2	8.0	12.0
12	10.9	1.1	9.0	12.8
24	6.4	1.2	4.4	8.5

^aBased on statistical modeling.

^bPost hoc analysis based on summary statistics.